Status:
COMPLETED
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine and vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuz...
Detailed Description
OBJECTIVES: Primary * Determine the overall response rate in patients with HER2/neu-overexpressing metastatic breast cancer treated with first- or second-line therapy comprising capecitabine, vinore...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed invasive breast cancer
- Metastatic disease
- HER2/neu-positive by immunohistochemistry (3+ by HercepTest\^™ or equivalent) OR positive for amplification by fluorescent in situ hybridization
- Testing may be performed in the primary tumor or the metastatic site
- Received prior anthracycline or taxane as adjuvant therapy or for metastatic disease
- Measurable disease
- At least one measurable lesion ≥ 2.0 cm by CT scan or MRI OR ≥ 1.0 cm by spiral CT scan
- The following are considered non-measurable disease:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- No bone metastases as the only evidence of metastasis
- Previously treated CNS metastases allowed provided disease has been stable for ≥ the past 3 months
- Hormone receptor status:
- Not specified
- PATIENT CHARACTERISTICS:
- Age
- 18 and over
- Sex
- Female or male
- Performance status
- ECOG 0-2
- Life expectancy
- At least 12 weeks
- Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm\^3
- Hemoglobin ≥ 8.0 g/dL
- Platelet count ≥ 100,000/mm\^3
- No known uncontrolled coagulopathy
- Hepatic
- Bilirubin ≤ 3.0 times the upper limit of normal (ULN)
- One of the following must be true:
- AST or ALT ≤ 5 times ULN AND alkaline phosphatase normal
- Alkaline phosphatase ≤ 5 times ULN AND AST or ALT normal
- Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
- INR ≤ 1.5 times ULN
- Renal
- Calcium ≤ 11.5 mg/dL
- Creatinine ≤ 1.5 times ULN
- Creatinine clearance ≥ 30 mL/min
- Cardiovascular
- LVEF ≥ 50% by MUGA or echocardiogram
- No clinically significant (i.e., active) cardiac disease
- No congestive heart failure
- No symptomatic coronary artery disease
- No myocardial infarction within the past 12 months
- No cardiac arrhythmia not controlled with medication
- Gastrointestinal
- Able to take oral medication
- No lack of physical integrity of the upper gastrointestinal tract
- No clinically significant malabsorption syndrome
- Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study participation
- No history of allergy or hypersensitivity to study drugs, drug product excipients, including polysorbate 80, or chemically similar agents
- No prior unanticipated severe reaction to fluoropyrimidine therapy
- No know hypersensitivity to fluorouracil
- No known dihydropyrimidine dehydrogenase deficiency
- No history of uncontrolled seizures or CNS disorders
- No clinically significant psychiatric disability that would preclude giving informed consent or study compliance
- No other serious uncontrolled infection or disease
- No other malignancy within the past 5 years except cured basal cell skin cancer, carcinoma in situ of the cervix, or contralateral breast cancer
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- Prior adjuvant trastuzumab (Herceptin\^®) allowed as adjuvant or first-line therapy for metastatic disease
- No concurrent immunotherapy
- Chemotherapy
- See Disease Characteristics
- No more than 1 prior chemotherapy regimen in the advanced or metastatic (non-adjuvant) setting
- No prior continuous (≥ 24 hours) fluorouracil infusion
- No prior capecitabine
- No prior oral fluoropyrimidines (e.g., eniluracil and fluorouracil, uracil and tegafur, S1, or emitefur)
- Endocrine therapy
- At least 1 day since prior hormonal therapy
- No concurrent hormonal therapy
- Radiotherapy
- More than 4 weeks since prior radiotherapy to the axial skeleton (i.e., skull, spinal column, sternum, or ribs)
- No concurrent radiotherapy
- Surgery
- More than 4 weeks since prior major surgery
- No prior organ allografts requiring immunosuppressive therapy
- Other
- More than 4 weeks since prior investigational drugs
- No concurrent sorivudine or its chemically related analogues (e.g., brivudine)
- No concurrent allopurinol, metronidazole, or cimetidine
- No other concurrent cytotoxic agents
- No other concurrent investigational drugs
- No other concurrent anticancer therapy
Exclusion
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00093808
Start Date
August 1 2004
End Date
May 1 2013
Last Update
March 6 2017
Active Locations (147)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States, 85259-5499
2
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States, 32224
3
Rush-Copley Cancer Care Center
Aurora, Illinois, United States, 60504
4
St. Joseph Medical Center
Bloomington, Illinois, United States, 61701